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Microsatellite instability (MSI), characterized by contraction or expansion in microsatellite length or short tandem repeats compared with germline lengths, is found in 85% to
Microsatellites are repeating sequences of 1-to 6-basepair subunits interspersed throughout the genome that are useful markers for genetic mapping, forensic analysis, and bone marrow engraftment monitoring. Microsatellite instability (MSI) in tumors, also known as replication errors, is the contraction or expansion of microsatellite lengths in the tumor relative to germline lengths and is a functional marker of mismatch repair defects. 1 MSI is present in 85% to 90% of colorectal tumors arising within families with hereditary nonpolyposis colorectal cancer (HNPCC), 2,3 a condition most commonly due to germline mutations in DNA mismatch repair genes. MSI also has been reported to occur at a lower frequency in common, nonhereditary forms of other malignant neoplasms, including tumors of the gastrointestinal tract, endometrium, lung, ovary, brain, and breast. [4] [5] [6] [7] [8] [9] Promoter methylation at hMLH1 has been reported to be an important mechanism in MSI-positive sporadic colorectal cancer [10] [11] [12] and endometrial cancer. 13, 14 The mechanisms causing MSI in sporadic tumors have not been elucidated completely and, possibly, may involve genes or pathways different from those implicated in HNPCC. The mechanism of MSI may be tumor-type specific and have different clinical implications for HNPCC and sporadic cancers.
Typical medullary carcinoma of the breast is characterized morphologically by tumor cells with high-grade nuclear atypia, numerous mitoses, and a predominantly syncytial-like growth pattern. These tumors are sharply circumscribed and are associated with a marked mononuclear infiltrate. Tumors with features of typical medullary carcinoma that demonstrate focal irregular infiltration of surrounding stroma and have only a mild mononuclear infiltrate or contain prominent fibrous bands are sometimes classified as atypical medullary carcinoma. 15 Medullary breast cancer is distinguished clinically, in many series, from infiltrating ductal carcinoma by its generally better prognosis compared with similar tumors lacking a medullary growth pattern. 16, 17 Nevertheless, the atypical and typical medullary carcinomas share several distinctive morphologic features, suggesting that the pathogenesis of these neoplasms may be closely related.
The reported incidence of MSI in breast cancers is 5% to 30%. [18] [19] [20] [21] [22] [23] [24] However, studies vary greatly in the types and number of loci studied, the criteria for defining MSI, and the histologic subtypes of breast cancer analyzed. The majority of studies have analyzed common infiltrating ductal or lobular carcinoma, [18] [19] [20] 22, 23 and data are limited on the incidence of MSI in the relatively rare medullary subtype. 25 Colorectal cancer associated with HNPCC commonly exhibits medullary features with a prominent lymphoid infiltrate, 26, 27 in addition to MSI. It was initially thought that pathologic features might be used as a surrogate for MSI positivity with a certain degree of accuracy. 26, 28 In addition to this association, there are data to suggest that a rare medullary subtype of pancreatic carcinoma is more likely to demonstrate MSI than the more common nonmedullary variety. 29 Given these observations, we postulated that the medullary phenotype might correlate in general with MSI and that medullary breast carcinoma might demonstrate significant MSI compared with other histologic subtypes of breast cancer.
At a 1997 National Cancer Institute-organized conference, a group proposed a set of microsatellite markers that were validated to detect MSI in colon cancer. 30 Since then, this panel has been further validated to detect MSI in additional tumor types. We wanted to test whether the panel could detect MSI in medullary breast cancer, and, thus, we analyzed a series of medullary breast cancer cases for MSI using the panel of loci that is considered standard for colorectal cancer. Historic data have shown that instability of these markers in colon cancer correlated with defective mismatch repair, primarily from defects in the 2 mismatch repair genes hMLH1 and hMSH2. [31] [32] [33] [34] [35] 
Materials and Methods
Patients and Samples
Archival, paraffin-embedded material from the surgical pathology files of the Johns Hopkins University, Baltimore, MD, was used for the study. Samples consisted of medullary breast carcinoma and histologically negative lymph nodes. Histologic features were reviewed in detail and independently confirmed by one of us (M.E.S.). The diagnosis of medullary carcinoma was based on a modification of criteria proposed by Tavassoli. 15 Cases were classified as typical medullary carcinoma if the tumor consisted of a circumscribed mass of cells with high-grade nuclear atypia growing in predominantly syncytial-like arrangements in association with a moderate or dense lymphoplasmacytic infiltrate. Tumors with focal microscopic infiltration of surrounding stroma, dense fibrous bands, or a mild to moderate inflammatory infiltrate were classified as atypical medullary carcinoma.
Microsatellite Analysis
Tissue from tumor sections showing medullary features was dissected from adjacent tissues to enrich for tumor DNA. Tissue from tumor-negative lymph node sections was used as a source of germline DNA. Following deparaffinization with xylene, DNA was isolated using standard Proteinase K digestion and ethanol precipitation. 36 DNA was amplified for the 5 primary microsatellite loci (BAT25, BAT26, D17S250, D5S346, and D2S123) recommended by the National Cancer Institute-sponsored workshop 30 for diagnosis of MSI in colorectal cancer in a single, multiplexed polymerase chain reaction (PCR), as described by Berg et al. 37 We also analyzed the tumors for MSI in 3 additional alternative loci, BAT40, D18S55, and D18S58, in monoplex reactions. For the monoplex reactions, the total reaction volume was 10 µL and was composed of 1× PCR buffer (Applied Biosystems, Foster City, CA), 2 nmol of deoxynucleotide triphosphate (Applied Biosystems), 1 U of AmpliTaq Gold DNA polymerase (Applied Biosystems), primer (Research Genetics, Huntsville, AL) mixes of 1:15 forward/reverse primer molar ratio as listed in ❚Table 1❚, and 150 ng of template DNA. Amplification conditions were similar to those used in the multiplexed reaction for the 5 primary loci. The PCR products were analyzed by capillary gel electrophoresis with automated fluorescent fragment analysis on an ABI 310 genetic analyzer (Applied Biosystems).
We defined the tumors to be microsatellite stable when no novel alleles were present in the tumor compared with the germline pattern in any of the 8 loci. MSI in only 1 of the 8 loci analyzed would be interpreted as MSI-low. In this breast cancer study, we designated the tumor to be MSI-high if 2 or more markers were shifted.
Results
We analyzed 8 cases of medullary breast carcinoma for MSI at 8 microsatellite markers. Four of 8 cases were typical medullary carcinoma, and 4 were atypical medullary carcinoma. The clinical and pathologic characteristics and results of the microsatellite analyses are summarized in ❚Table 2❚. The mean age at tumor diagnosis was 49.6 years (range, 38-75 years), and the mean tumor size was 2.16 cm (range, 1-4.5 cm). The majority of tumors were negative for estrogen and progesterone receptors (4/7 negative for estrogen receptor; 5/7 negative for progesterone receptor) and nodenegative (4/5). Adequate amplification was attained at all 8 loci for the 8 tumor-lymph node pairs with the exception of 2 tumor specimens at the BAT40 locus and 1 normal lymph node specimen at the D2S123 locus. All 8 cases were microsatellite stable for all markers that amplified. A sample of the electropherogram for the multiplexed PCR is shown in ❚Figure 1❚.
Discussion
We found all 8 typical and atypical medullary breast cancer cases in our study to be stable at 3 mononucleotide and 5 dinucleotide repeat sequences. The low incidence of MSI in our study is in keeping with what has been reported in the literature for breast cancer in general. It also is in concordance with the only other systematic study examining the incidence of MSI in medullary breast cancer in which 24 medullary breast cancer specimens were examined, and only 2 had minor shifts at the BAT26 mononucleotide repeat locus. 25 Several series have suggested an association in breast adenocarcinomas between MSI and poor clinicopathologic prognostic features, namely, larger tumor size, 21, 22 positive nodal status, [21] [22] [23] advanced stage, 21 negative expression of hormone receptors, 38 and reduced disease-free and overall survival. 21 Two studies suggested MSI to be more commonly observed with lobular-type histologic features. 22 Medullary and variants of medullary breast carcinoma are more common in women with BRCA mutations. The issue of whether familial breast cancer is more likely to demonstrate MSI than sporadic breast cancer is unresolved. Glebov et al 40 reported MSI to be more common in familial breast cancer, whereas Jonsson et al 18 reported no difference in incidence between sporadic and familial breast cancer. Studies of MSI in bilateral breast cancer 41 and in young patients with breast cancer 42 have reported an incidence similar to that reported in the literature for breast cancer as a whole. The incidence of MSI in familial breast cancer due to a common founder mutation in the BRCA2 gene in the Icelandic population has been systematically studied and was found to be very low (4/106). 43 All 4 MSI-positive cases in this BRCA2 study had ductal histologic features. 43 It is conceivable that failure to demonstrate significant MSI in our study and others may be attributed to inappropriate choice of microsatellite markers, because the mechanisms leading to MSI may differ between breast and colorectal cancer. Although 1 study suggested that MSI is more commonly observed at trinucleotide repeat loci in breast cancer, 20 Schmitt et al 25 found no instability in 8 tetranucleotide and 1 pentanucleotide repeat sequences in 5 medullary breast carcinoma specimens that could be evaluated. Furthermore, Siah et al, 42 in a review of more than 300 microsatellite loci in breast tumors, reported that the size of the microsatellite repeat unit was not associated with the frequency of detecting MSI. Siah et al 42 suggested that some loci may be more informative than others in the analysis of breast cancer, including the D17S250 locus, one of the markers used in our study. Therefore, we doubt that the lack of MSI in medullary breast cancer is an artifact of our choice of markers.
We found no MSI in medullary breast cancer using a panel of mononucleotide and dinucleotide repeat sequences that is considered a reference panel for the diagnosis of hereditary colorectal cancer. Together, our data and those of Schmitt et al 25 suggest that only a minimal, if any, association exists between the medullary histologic phenotype in breast cancer and MSI. 
